Cue Biopharma ( CUE ) announced on Friday that it has appointed Lucinda Warren as interim President and CEO, succeeding Usman Azam, who stepped down from the roles effective March 26, 2026. Warren brings over 30 years of pharma and biotech experience, including senior roles at Johnson & Johnson , and currently serves as chairman of the board of International School Services . Shares -4.58%. More o...
Cue Biopharma ( CUE ) announced on Friday that it has appointed Lucinda Warren as interim President and CEO, succeeding Usman Azam, who stepped down from the roles effective March 26, 2026. Warren brings over 30 years of pharma and biotech experience, including senior roles at Johnson & Johnson , and currently serves as chairman of the board of International School Services . Shares -4.58%. More on Cue Biopharma Seeking Alpha’s Quant Rating on Cue Biopharma Historical earnings data for Cue Biopharma Financial information for Cue Biopharma
Just_Super/iStock via Getty Images It has been a while since I wrote abo ut Tiptree Inc. ( TIPT ). There hasn't been much to say. We are just waiting for the sale of Fortegra to close. That is expected in the late April to late May/early June timeframe. I don't believe there will be an antitrust issue. It's just a matter of regulatory approval, which I believe should be granted without any issues....
Just_Super/iStock via Getty Images It has been a while since I wrote abo ut Tiptree Inc. ( TIPT ). There hasn't been much to say. We are just waiting for the sale of Fortegra to close. That is expected in the late April to late May/early June timeframe. I don't believe there will be an antitrust issue. It's just a matter of regulatory approval, which I believe should be granted without any issues. Operations of Fortegra do not matter right now. All profits are trapped at the entity. They will be the buyer's unless the deal falls through. Should the deal not close before June, the purchase price increases at a 10% annual rate. Again, I don't expect that. The sale of Reliance has closed. After the Fortegra sale closes, management said in the Q4 earnings announcement that it will have a $24.40/share pile of cash. With the stock at $16.70, that is a 31.5% discount to cash value that should be attained in about 2 months at the latest. I know that some people are disappointed with the Fortegra sale price. Frankly, I am, too. My previous estimates of value clearly assumed higher multiples of earnings. However, I have no doubts that management got the best price available. Management has discussed their concerns about a softening insurance underwriting environment. Companies like Kinsale ( KNSL ) and Skyward ( SKWD ) have reflected that softening. I believe that is why the sales price underwhelmed some people. No matter the price, the fact of the matter is that the deal is likely to close, and there will be cash of $24.40 on the balance sheet with no debt or other liabilities. As important, the company has cut a lot of overhead, enough that with the cash in T-Bills, the interest will more than cover corporate overhead. I am also of the belief that if the stock is at a level where management can buy it at close to a 1/3 discount from the cash value, that will represent a 50% return on any shares it buys, and it will do so aggressively at that level. In addition, every share ...
JHVEPhoto/iStock Editorial via Getty Images Introduction Broadcom ( AVGO ) builds Serializer/Deserializer (“SerDes”) into the chips they co-design with customers, enabling high-speed connections between them within AI clusters. The analog circuits in the SerDes receiver do the preliminary work of amplifying and shaping the degraded signal before handing it off to digital signal processing (“DSP”)....
JHVEPhoto/iStock Editorial via Getty Images Introduction Broadcom ( AVGO ) builds Serializer/Deserializer (“SerDes”) into the chips they co-design with customers, enabling high-speed connections between them within AI clusters. The analog circuits in the SerDes receiver do the preliminary work of amplifying and shaping the degraded signal before handing it off to digital signal processing (“DSP”). In order to more fully reconstruct the received signal, DSP runs sophisticated algorithms. Nvidia ( NVDA ) designs AI factories built around GPUs, networking, and software. Broadcom co-designs XPUs, which are a particular type of application-specific integrated circuit (“ASICs”). Ostensibly the TPUs Broadcom co-designs with Google ( GOOG ) ( GOOGL ) are ASICs and XPUs, but Google is Broadcom’s largest customer, and their TPUs are often treated as a separate category. XPUs generally refer to the broad category of custom accelerators co-designed with Meta Platforms ( META ) and others. My thesis is that Broadcom’s expertise in SerDes and DSP drives success in an AI world. Broadcom’s fiscal 2025 went through November 2, 2025. As such, their fiscal quarters are almost two months ahead of calendar quarters. For example, fiscal Q1 2026 goes through February 1, 2026, instead of March 31, 2026. SerDes And DSP Broadcom is a leader in terms of serializing data from a chip, which is basically merging multiple wires/lanes. The data is then deserialized or unpacked as it arrives at the other end on another chip. Speed is critical, and power is a constraint. Part of the end of the SerDes process is DSP - the stage when the received signal is more fully cleaned and processed. Physical Layer Products General Manager Vijay Janapaty explained why Broadcom is the world leader with SerDes at the Enabling AI Infrastructure event in March 2024. He explains how Broadcom had a history of driving the best SerDes in the industry for at least four generations leading up to the event. There are four ...
hanibaram/iStock via Getty Images Aurinia Pharmaceuticals ( AUPH ) is under new management, with activist investor and life sciences fund manager Kevin Tang taking over the CEO role from Peter Greenleaf. In December 2025, I noted AUPH's Lupkynis continued to deliver sales growth but noted potential competition from the launch of a competing drug, Gazyva, rating AUPH a hold. This article looks at t...
hanibaram/iStock via Getty Images Aurinia Pharmaceuticals ( AUPH ) is under new management, with activist investor and life sciences fund manager Kevin Tang taking over the CEO role from Peter Greenleaf. In December 2025, I noted AUPH's Lupkynis continued to deliver sales growth but noted potential competition from the launch of a competing drug, Gazyva, rating AUPH a hold. This article looks at the management shakeup, updated Lupkynis performance, and recent financials to see where the company stands now. A new leader On March 23, 2026, AUPH announced that Kevin Tang would be the new CEO of the company. Peter Greenleaf, the outgoing CEO, would stay on as a consultant for the transition but has also resigned from the Board of Directors. Tang is an activist investor as well as the president of Tang Capital Management LLC, who joined AUPH's board in September 2024 and was subsequently appointed Chair of the board. Tang doesn't just run a fund; he has a track record of founding/co-founding and running biotechs. For example, Tang was Chairman at La Jolla Pharmaceutical Company from 2014 to 2022 and founded Odonate Therapeutics in 2013, serving as Chairman and CEO there until 2022. Tang's appointment can also help the company reduce its expenses further, as he won't receive a salary. Mr. Tang has elected to not receive any salary, bonuses, equity awards or other compensation from Aurinia. AUPH 8-K filing , March 23, 2026. It should be noted that Tang Capital Partners, LP, and Tang Capital Partners International own between them ~12.2M shares of AUPH as of March 3, 2026, as disclosed in a Form 4 filed on March 3. The filing notes Tang Capital, LP, acquired a further 900,000 shares at prices between $13.97 and $14.61 between February 27 and March 3, 2026. Tang's firm then had been acquiring shares on the open market aggressively just about a month ago. Indeed, a Schedule 13D/A filing notes that since March 4, 2025, the Tang investment funds had expended ~$26.3M to acquire ...
(RTTNews) - Stocks moved sharply lower over the course of the trading day on Friday, adding to the steep losses posted in the previous session. The major averages moved to the downside early in the session and slid even more firmly into negative territory as the day progressed.
(RTTNews) - Stocks moved sharply lower over the course of the trading day on Friday, adding to the steep losses posted in the previous session. The major averages moved to the downside early in the session and slid even more firmly into negative territory as the day progressed.
NVIDIA Corp.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers NVIDIA Corp. (NASDAQ: NVDA) as worthy of further study and has named the company its "Stock to Study" for the June/July 2026 issue for investors' informational and educational u...
NVIDIA Corp.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers NVIDIA Corp. (NASDAQ: NVDA) as worthy of further study and has named the company its "Stock to Study" for the June/July 2026 issue for investors' informational and educational use.
FilippoBacci U.S. stocks ended Friday broadly lower, with selling pressure intensifying across sectors as investors weighed persistent geopolitical risks tied to tensions in the Middle East. Market sentiment remained fragile after President Donald Trump extended the pause on potential strikes targeting Iran’s energy infrastructure through April, a move that has prolonged uncertainty rather than ea...
FilippoBacci U.S. stocks ended Friday broadly lower, with selling pressure intensifying across sectors as investors weighed persistent geopolitical risks tied to tensions in the Middle East. Market sentiment remained fragile after President Donald Trump extended the pause on potential strikes targeting Iran’s energy infrastructure through April, a move that has prolonged uncertainty rather than easing it. The technology-heavy Nasdaq Composite ( COMP:IND ) led declines, dropping 2.1%, while the S&P 500 ( SP500 ) fell 1.6%. The Dow Jones Industrial Average ( DJI ) also retreated 1.7%, reflecting a broad-based pullback as traders reduced exposure to risk assets heading into the weekend. Despite the overall weakness, some pockets of the market showed relative resilience to a degree. Alex King of Cestrian Capital Research pointed out the semiconductor space, as the stocks outperformed on a relative basis, suggesting selective buying interest even as major indices slipped to fresh cycle lows. “Rather strangely, the semiconductor sector had a less bad week than the S&P or the Nasdaq,” said King said. King also added that while markets may face further volatility in the near term, a sharp rebound could eventually follow. For now, however, “patience is the name of this game,” as investors should remain cautious at the moment. How do you think about gold as an investment? Share your opinion in our user poll . Market Tracking ETFs: ( DIA ), ( DDM ), ( DOG ), ( DXD ), ( SDOW ), ( SPY ), ( VOO ), ( IVV ), ( RSP ), ( SSO ), ( UPRO ), ( SH ), ( SDS ), ( SPXU ), ( QQQ ), ( QQQM ), ( TQQQ ), ( QID ), and ( SQQQ ). More on markets Dividend Roundup: Micron Technology, Cisco, Nucor, Freeport-McMoRan, and more Treasury Yields spike to multi-month highs as the 10-year tops 4.48% 20 dividend stocks to watch as the Middle East conflict continues to shake markets Citi holds firm on S&P 500 target despite Iran tensions and the current market pullback OECD lifts G20 inflation outlook as risin...